Motif mediated protein-protein interactions as drug targets

Cell Communication and Signaling

Volumn 14, Issue 1, 2016, Pages

  Corbi Verge, Carles ^a   Kim, Philip M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Drug discovery; Linear motifs; Peptides as therapeutics; Peptidomimetics; Protein protein interactions; Small molecule inhibitors

Indexed keywords

BH3 PROTEIN; CILENGITIDE; INHIBITOR OF APOPTOSIS PROTEIN; MACROCYCLIC COMPOUND; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; X LINKED INHIBITOR OF APOPTOSIS; MOLECULAR LIBRARY; PEPTIDOMIMETIC AGENT;

BINDING AFFINITY; CLINICAL TRIAL (TOPIC); DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG TARGETING; HUMAN; INTRACELLULAR SPACE; MOLECULAR SIZE; NONHUMAN; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ANALYSIS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; MOLECULAR LIBRARY; MOLECULAR MODEL; PHARMACOLOGY; PROCEDURES; PROTEIN DOMAIN;

ANIMALS; DRUG DISCOVERY; HUMANS; MACROCYCLIC COMPOUNDS; MODELS, MOLECULAR; PEPTIDOMIMETICS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPS; SMALL MOLECULE LIBRARIES;

EID: 84959477641     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-016-0131-4     Document Type: Review

References (140)

1. Keskin O, Gursoy A, Ma B, Nussinov R. Principles of protein-protein interactions: what are the preferred ways for proteins to interact? Chem Rev. 2008;108:1225-44.
2. Stein A, Aloy P. Novel peptide-mediated interactions derived from high-resolution 3-dimensional structures. PLoS Comput Biol. 2010;6:e1000789.
3. Gerrard JA, Hutton CA, Perugini MA. Inhibiting protein-protein interactions as an emerging paradigm for drug discovery. Mini Rev Med Chem. 2007;7:151-7.
4. Diella F. Understanding eukaryotic linear motifs and their role in cell signaling and regulation. Front Biosci. 2008;13:6580-603.
5. Bellay J, Michaut M, Kim T, Han S, Colak R, Myers CL, Kim PM. An omics perspective of protein disorder. Mol Biosyst. 2012;8:185-93.
6. Villoutreix BO, Kuenemann MA, Poyet J-L, Bruzzoni-Giovanelli H, Labbé C, Lagorce D, et al. Drug-like protein-protein interaction modulators: challenges and opportunities for drug discovery and chemical biology. Mol Inform. 2014;33:414-37.
7. Arimura T, Nakamura T, Hiroi S, Satoh M, Takahashi M, Ohbuchi N, Ueda K, Nouchi T, Yamaguchi N, Akai J, Matsumori A, Sasayama S, Kimura A. Characterization of the human nebulette gene: a polymorphism in an actin-binding motif is associated with nonfamilial idiopathic dilated cardiomyopathy. Hum Genet. 2000;107:440-51.
8. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010;20:299-309.
9. Müller D, Kausalya PJ, Claverie-Martin F, Meij IC, Eggert P, Garcia-Nieto V, et al. A novel claudin 16 mutation associated with childhood hypercalciuria abolishes binding to ZO-1 and results in lysosomal mistargeting. Am J Hum Genet. 2003;73:1293-301.
10. Bolz H, Bolz S-S, Schade G, Kothe C, Mohrmann G, Hess M, Gal A. Impaired calmodulin binding of myosin-7A causes autosomal dominant hearing loss (DFNA11). Hum Mutat. 2004;24:274-5.
11. Uyar B, Weatheritt RJ, Dinkel H, Davey NE, Gibson TJ. Proteome-wide analysis of human disease mutations in short linear motifs: neglected players in cancer? Mol Biosyst. 2014;10:2626-42.
12. Eudy JD, Sumegi J. Molecular genetics of Usher syndrome. Cell Mol Life Sci. 1999;56:258-67.
13. Furuhashi M, Kitamura K, Adachi M, Miyoshi T, Wakida N, Ura N, Shikano Y, Shinshi Y, Sakamoto K-I, Hayashi M, Satoh N, Nishitani T, Tomita K, Shimamoto K. Liddle's syndrome caused by a novel mutation in the proline-rich PY motif of the epithelial sodium channel beta-subunit. J Clin Endocrinol Metab. 2005;90:340-4.
14. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, López Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39:1007-12.
15. Davey NE, Travé G, Gibson TJ. How viruses hijack cell regulation. Trends Biochem Sci. 2011;36:159-69.
16. Urata S, Noda T, Kawaoka Y, Morikawa S, Yokosawa H, Yasuda J. Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. J Virol. 2007;81:4895-9.
17. Trible RP, Emert-Sedlak L, Smithgall TE. HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction. J Biol Chem. 2006;281:27029-38.
18. Cory S, Adams JM. The bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647-56.
19. Fry DC, Graves B, Vassilev LT. Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects. Meth Enzymol. 2005;399:622-33.
20. Rayburn E, Zhang R, He J, Wang H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. CCDT. 2005;5:27-41.
21. Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9:459-70.
22. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
23. Park J-E, Kong D, Fisher R, Cardellina J, Shoemaker RH, Melillo G. Targeting the PAS-A domain of HIF-1α for development of small molecule inhibitors of HIF-1. Cell Cycle. 2014;5:1847-53.
24. Cochran AG. Antagonists of protein-protein interactions. Chem Biol. 2000;7:R85-94.
25. Cesa LC, Patury S, Komiyama T, Ahmad A, Zuiderweg ERP, Gestwicki JE. Inhibitors of difficult protein-protein interactions identified by high-throughput screening of multiprotein complexes. ACS Chem Biol. 2013;8:1988-97.
26. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem Int Ed. 2005;44:4130-63.
27. Murray JK, Gellman SH. Targeting protein-protein interactions: lessons from p53/MDM2. Biopolymers. 2007;88:657-86.
28. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, Caffrey DR, Salzberg AC, Huang ES. Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol. 2007;25:71-5.
29. Verdine GL, Walensky LD. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clin Cancer Res. 2007;13:7264-70.
30. Sillerud LO, Larson RS. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. Curr Protein Pept Sci. 2005;6:151-69.
31. Baran I, Varekova RS, Parthasarathi L, Suchomel S, Casey F, Shields DC. Identification of potential small molecule peptidomimetics similar to motifs in proteins. J Chem Inf Model. 2007;47:464-74.
32. Nieddu E, Pasa S. Interfering with protein-protein contact: molecular interaction maps and peptide modulators. Curr Top Med Chem. 2007;7:21-32.
33. Vagner J, Qu H, Hruby VJ. Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol. 2008;12:292-6.
34. Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chemical Infor. 2013;81:136-47.
35. Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol. 2012;52:549-73.
36. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711-5.
37. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein|[ndash]|protein interfaces. Nature. 2007;450:1001-9.
38. Hajduk PJ, Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov. 2007;6:211-9.
39. Sprinzak E, Altuvia Y, Margalit H. Characterization and prediction of protein-protein interactions within and between complexes. Proc Natl Acad Sci. 2006;103:14718-23.
40. Ivarsson Y, Arnold R, McLaughlin M, Nim S, Joshi R, Ray D, et al. Large-scale interaction profiling of PDZ domains through proteomic peptide-phage display using human and viral phage peptidomes. Proc Natl Acad Sci U S A. 2014;111:2542-7.
41. Bartoli S, Fincham CI, Fattori D. Fragment-based drug design: combining philosophy with technology. Curr Opin Drug Discov Devel. 2007;10:422-9.
42. Cukuroglu E, Engin HB, Gursoy A, Keskin O. Hot spots in protein-protein interfaces: towards drug discovery. Prog Biophys Mol Biol. 2014;116:165-73.
43. Morton D, Leach S, Cordier C, Warriner S, Nelson A. Synthesis of natural-product-like molecules with over eighty distinct scaffolds. Angew Chem Int Ed. 2009;48:104-9.
44. Yip KY, Utz L, Sitwell S, Hu X, Sidhu SS, Turk BE, Gerstein M, Kim PM. Identification of specificity determining residues in peptide recognition domains using an information theoretic approach applied to large-scale binding maps. BMC Biol. 2011;9:53.
45. Keskin O, Nussinov R. Similar binding sites and different partners: implications to shared proteins in cellular pathways. Structure. 2007;15:341-54.
46. Teyra J, Kim PM. Interpreting protein networks with three-dimensional structures. Nat Meth. 2012;10:43-4.
47. Nobeli I, Favia AD, Thornton JM. Protein promiscuity and its implications for biotechnology. Nat Biotechnol. 2009;27:157-67.
48. Keserü GM, Swinney DC. Thermodynamics and Kinetics of Drug Binding. Edited by György M. Keseru and David C. Swinney. ChemMedChem. 2015;10:1764-5.
49. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2; - fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 1994;9:2523-9.
50. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303:844-8.
51. Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, Sun D, Wang S. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem. 2013;56:5553-61.
52. Bernard D, Zhao Y, Wang S. AM-8553: a novel MDM2 inhibitor with a promising outlook for potential clinical development. J Med Chem. 2012;55:4934-5.
53. Werner L, Huang S, Armstrong EA, Francis D, Osgood T, Canon J, Harari PM. Abstract 2610: AMG 232, a small molecular inhibitor of MDM2 augments radiation response in human tumors harboring wild-type p53. Cancer Res. 2014;74:2610-0.
54. Galatin PS, Abraham DJ. A nonpeptidic sulfonamide inhibits the p53 - mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J Med Chem. 2004;47:4163-5.
55. Khoo KH, Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13:217-36.
56. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47-59.
57. Sattler M. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science. 1997;275:983-6.
58. Zinzalla G, Thurston DE. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med Chem. 2009;1:65-93.
59. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677-81.
60. Berg T. Modulation of protein-protein interactions with small organic molecules. Angew Chem Int Ed. 2003;42:2462-81.
61. Fletcher S, Hamilton AD. Protein-protein interaction inhibitors: small molecules from screening techniques. Curr Top Med Chem. 2007;7:922-7.
62. Vicent MJ, Pérez-Payá E, Orzáez M. Discovery of inhibitors of protein-protein interactions from combinatorial libraries. Curr Top Med Chem. 2007;7:83-95.
63. Fry DC, Wartchow C, Graves B, Janson C, Lukacs C, Kammlott U, Belunis C, Palme S, Klein C, Vu B. Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. ACS Med Chem Lett. 2013;4:660-5.
64. Van Molle I, Thomann A, Buckley DL, So EC, Lang S, Crews CM, et al. Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. Chem Biol. 2012;19:1300-12.
65. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DCS, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park C-M, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202-8.
66. Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. Leuk Lymphoma. 2015;56:2146-52.
67. Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013;23:139-41.
68. Shi Y, Wu G, Chai J, Suber TL, Wu J-W, Du C, Wang X. Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature. 2000;408:1008-12.
69. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20:122-8.
70. Link AJ, Mock ML, Tirrell DA. Non-canonical amino acids in protein engineering. Curr Opin Biotechnol. 2003;14:603-9.
71. Johnson JA, Lu YY, Van Deventer JA, Tirrell DA. Residue-specific incorporation of non-canonical amino acids into proteins: recent developments and applications. Curr Opin Chem Biol. 2010;14:774-80.
72. Leisle L, Valiyaveetil F, Mehl RA, Ahern CA. Incorporation of non-canonical amino acids. Adv Exp Med Biol. 2015;869:119-51.
73. Flygare JA, Fairbrother WJ. Small-molecule pan-IAP antagonists: a patent review. Expert Opin Ther Patents. 2010;20:251-67.
74. Spokoyny AM, Zou Y, Ling JJ, Yu H, Lin Y-S, Pentelute BL. A perfluoroaryl-cysteine SNAr chemistry approach to unprotected peptide stapling. J Am Chem Soc. 2013;135:5946-9.
75. Schafmeister CE, Po J, Verdine GL. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J Am Chem Soc. 2000:5891-5892.
76. Rabideau AE, Pentelute BL. A d-amino acid at the N-terminus of a protein abrogates its degradation by the N-end rule pathway. ACS Cent Sci. 2015;1:423-30.
77. Hamase K. Recent advances on D-amino acid research. J Pharm Biomed Anal. 2015;116:1.
78. Oddo A, Thomsen TT, Kjelstrup S, Gorey C, Franzyk H, Frimodt-Møller N, Løbner-Olesen A, Hansen PR. An amphipathic undecapeptide with all d-amino acids shows promising activity against colistin-resistant strains of acinetobacter baumannii and a dual mode of action. Antimicrob Agents Chemother. 2015;60:592-9.
79. Levi M, Hinkula J, Wahren B. A retro-inverso miniantibody with anti-HIV activity. AIDS Res Hum Retroviruses. 2000;16:59-65.
80. Zhang C, Dai P, Spokoyny AM, Pentelute BL. Enzyme-catalyzed macrocyclization of long unprotected peptides. Org Lett. 2014;16:3652-5.
81. Lennard KR, Tavassoli A. Peptides come round: using SICLOPPS libraries for early stage drug discovery. Chemistry. 2014;20:10608-14.
82. Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010;10:753-68.
83. Obiol Pardo C. Disrupting the protein-protein recognition in cancer pathways by molecular modeling. 2008. p. 1-238.
84. Sun H, Nikolovska-Coleska Z, Yang C-Y, Xu L, Tomita Y, Krajewski K, Roller PP, Wang S. Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. J Med Chem. 2004;47:4147-50.
85. Sun H, Nikolovska-Coleska Z, Yang C-Y, Xu L, Liu M, Tomita Y, Pan H, Yoshioka Y, Krajewski K, Roller PP, Wang S. Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc. 2004;126:16686-7.
86. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau M-J, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, Ostresh JM, Houghten RA, Reed JC. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 2004;5:25-35.
87. Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, Eckhardt SG, Elliott LO, Feng B, Franklin MC, Reisner SF, Gazzard L, Halladay J, Hymowitz SG, La H, LoRusso P, Maurer B, Murray L, Plise E, Quan C, Stephan J-P, Young SG, Tom J, Tsui V, Um J, Varfolomeev E, Vucic D, et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012;55:4101-13.
88. Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014;32:3103-10.
89. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res. 2009;7:1-11.
90. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip D, Goydos J, Haigh JJ, Haupt Y, Larue L, Jochemsen A, Shi H, Moriceau G, Lo RS, Ghanem G, Shackleton M, Bernal F, Marine J-C. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012;18:1239-47.
91. Macchiarulo A, Giacchè N, Carotti A, Moretti F, Pellicciari R. Expanding the horizon of chemotherapeutic targets: from MDM2 to MDMX (MDM4). Med Chem Comm. 2011;2:455-65.
92. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol. 2007;39:1476-82.
93. Dömling A. Small molecular weight protein-protein interaction antagonists - an insurmountable challenge? Curr Opin Chem Biol. 2008;12:281-91.
94. Shadfan M, Lopez-Pajares V, Yuan Z-M. MDM2 and MDMX: alone and together in regulation of p53. Transl Cancer Res. 2012;1:88-9.
95. Blackwell HE, Grubbs RH. Highly Efficient Synthesis of Covalently Cross-Linked Peptide Helices by Ring-Closing Metathesis. 1998;37(23):3281-3284.
96. Walensky LD, Bird GH. Hydrocarbon-stapled peptides: principles, practice, and progress. J Med Chem. 2014;57:6275-88.
97. Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL, Wahl GM, Walensky LD. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell. 2010;18:411-22.
98. Bernal F, Tyler AF, Korsmeyer SJ, Walensky LD, Verdine GL. Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc. 2007;129:2456-7.
99. Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To K-H, Olson KA, Kesavan K, Gangurde P, Mukherjee A, Baker T, Darlak K, Elkin C, Filipovic Z, Qureshi FZ, Cai H, Berry P, Feyfant E, Shi XE, Horstick J, Annis DA, Manning AM, Fotouhi N, Nash H, Vassilev LT, Sawyer TK. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A. 2013;110:E3445-54.
100. Stewart ML, Fire E, Keating AE, Walensky LD. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol. 2010;6:595-601.
101. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, Korsmeyer SJ. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004;305:1466-70.
102. Patgiri A, Yadav KK, Arora PS, Bar-Sagi D. An orthosteric inhibitor of the Ras-Sos interaction. Nat Chem Biol. 2011;7:585-7.
103. Leshchiner ES, Parkhitko A, Bird GH, Luccarelli J, Bellairs JA, Escudero S, Opoku-Nsiah K, Godes M, Perrimon N, Walensky LD. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc Natl Acad Sci U S A. 2015;112:1761-6.
104. Lafont V, Armstrong AA, Ohtaka H, Kiso Y, Mario Amzel L, Freire E. Compensating enthalpic and entropic changes hinder binding affinity optimization. Chemical Infor. 2007;69:413-22.
105. Pierschbacher MD, Ruoslahti E. Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion. 1987;262(36):17294-17298.
106. Kessler H, Gratias R, Hessler G, Gurrath M, Müller G. Conformation of cyclic peptides. Principle concepts and the design of selectivity and superactivity in bioactive sequences by "spatial screening". 1996;68(6).
107. Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA, New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012;118:5601-7.
108. Grillo-Bosch D, Choquet D, Sainlos M. Inhibition of PDZ domain-mediated interactions. Drug Discov Today Technol. 2013;10:e531-40.
109. Khan Z, Lafon M. PDZ domain-mediated protein interactions: therapeutic targets in neurological disorders. Curr Med Chem. 2014;21:2632-41.
110. Chen X, Longgood JC, Michnoff C, Wei S, Frantz DE, Bezprozvanny L. High-throughput screen for small molecule inhibitors of Mint1-PDZ domains. Assay Drug Dev Technol. 2007;5:769-83.
111. Opitz R, Müller M, Reuter C, Barone M, Soicke A, Roske Y, Piotukh K, Huy P, Beerbaum M, Wiesner B, Beyermann M, Schmieder P, Freund C, Volkmer R, Oschkinat H, Schmalz H-G, Kühne R. A modular toolkit to inhibit proline-rich motif-mediated protein-protein interactions. Proc Natl Acad Sci U S A. 2015;112:5011-6.
112. Balakin KV, Ivanenkov YA, Savchuk NP. Compound library design for target families. Methods Mol Biol. 2009;575:21-46.
113. McGovern SL, Helfand BT, Feng B, Shoichet BK. A specific mechanism of nonspecific inhibition. J Med Chem. 2003;46:4265-72.
114. Erlanson DA, Braisted AC, Raphael DR, Randal M, Stroud RM, Gordon EM, et al. Site-directed ligand discovery. Proc Natl Acad Sci U S A. 2000;97:9367-72.
115. Erlanson DA, Wells JA, Braisted AC. Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct. 2004;33:199-223.
116. Wang N, Majmudar CY, Pomerantz WC, Gagnon JK, Sadowsky JD, Meagher JL, et al. Ordering a dynamic protein via a small-molecule stabilizer. J Am Chem Soc. 2013;135:3363-6.
117. Lodge JM, Rettenmaier TJ, Wells JA, Pomerantz WC, Mapp AK. FP tethering: a screening technique to rapidly identify compounds that disrupt protein-protein interactions. Med Chem Comm. 2014;5:370-5.
118. Horswill AR, Savinov SN, Benkovic SJ. A systematic method for identifying small-molecule modulators of protein-protein interactions. Proc Natl Acad Sci U S A. 2004;101:15591-6.
119. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
120. O'Callaghan K, Kuliopulos A, Covic L. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem. 2012;287:12787-96.
121. Khan I, Khan M, Umar MN, Oh D-H. Nanobiotechnology and its applications in drug delivery system: a review. IET Nanobiotechnol. 2015;9:396-400.
122. Debele TA, Peng S, Tsai H-C. Drug carrier for photodynamic cancer therapy. Int J Mol Sci. 2015;16:22094-136.
123. Mou X, Ali Z, Li S, He N. Applications of magnetic nanoparticles in targeted drug delivery system. J Nanosci Nanotechnol. 2015;15:54-62.
124. Cronican JJ, Beier KT, Davis TN, Tseng J-C, Li W, Thompson DB, et al. A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo. Chem Biol. 2011;18:833-8.
125. Liao X, Rabideau AE, Pentelute BL. Delivery of antibody mimics into mammalian cells via anthrax toxin protective antigen. Chembiochem. 2014;15:2458-66.
126. Rabideau AE, Liao X, Pentelute BL. Delivery of mirror image polypeptides into cells. Chem Sci. 2015;6:648-53.
127. Bechara C, Sagan S. Cell-penetrating peptides: 20 years later, where do we stand? FEBS Lett. 2013;587:1693-702.
128. Tokonzaba E, Capelluto DGS, Kutateladze TG, Overduin M. Phosphoinositide, phosphopeptide and pyridone interactions of the Abl SH2 domain. Chemical Infor. 2006;67:230-7.
129. Skotland T, Iversen TG, Torgersen ML, Sandvig K. Cell-penetrating peptides: possibilities and challenges for drug delivery in vitro and in vivo. Molecules. 2015;20:13313-23.
130. Chorev M. The partial retro-inverso modification: a road traveled together. Pept Sci. 2005;80:67-84.
131. Liu M, Li C, Pazgier M, Li C, Mao Y, Lv Y, Gu B, Wei G, Yuan W, Zhan C, Lu W-Y, Lu W. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A. 2010;107:14321-6.
132. Linde Y, Ovadia O, Safrai E, Xiang Z, Portillo FP, Shalev DE, Haskell-Luevano C, Hoffman A, Gilon C. Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Biopolymers. 2008;90:671-82.
133. Chatterjee J, Gilon C, Hoffman A, Kessler H. N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res. 2008;41:1331-42.
134. Shekhawat SS, Ghosh I. Split-protein systems: beyond binary protein-protein interactions. Current Opinion in Chemical Biology. 2011;15(6):789-797.
135. Lam MHY, Stagljar I. Strategies for membrane interaction proteomics: no mass spectrometry required. Proteomics. 2012;12:1519-26.
136. Tonikian R, Zhang Y, Boone C, Sidhu SS. Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries. Nat Protoc. 2007;2:1368-86.
137. Luck K, Travé G. Phage display can select over-hydrophobic sequences that may impair prediction of natural domain-peptide interactions. Bioinformatics. 2011;27:899-902.
138. Weisberg E, Sattler M. A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3. Haematologica. 2012;97:1620-1.
139. Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, Kremyanskaya M, Najfeld V, Hoffman R. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012;120:3098-105.
140. Kim Y-H, Lee JK, Kim B, DeWitt JP, Lee JE, Han JH, Kim S-K, Oh CW, Kim C-Y. Combination therapy of cilengitide with belotecan against experimental glioblastoma. Int J Cancer. 2013;133:749-56.